PHASE-II STUDY OF AMONAFIDE IN THE TREATMENT OF PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND THE NECK - AN ILLINOIS-CANCER-CENTER STUDY
F. Rosen et al., PHASE-II STUDY OF AMONAFIDE IN THE TREATMENT OF PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND THE NECK - AN ILLINOIS-CANCER-CENTER STUDY, Investigational new drugs, 13(3), 1995, pp. 249-252
Amonafide (nafidimide), a synthetic organic compound with an inhibitor
y effect on cellular replication, was used in a phase II study conduct
ed by the Illinois Cancer Center in order to assess its efficacy and t
oxicity in advanced or recurrent squamous cell cancer of the head and
neck. Eligible patients had received no more than one prior adjuvant o
r neoadjuvant chemotherapy, had normal bone marrow, renal and hepatic
function, ECOG performance status of 0-2, and bidimensionally measurab
le disease. Eligible patients were administered amonafide at a startin
g dose of 300 mg/m(2) for five consecutive days every 3 weeks with dos
e escalation or de-escalation according to established hematologic cri
teria in the absence of disease progression. Nineteen of 22 entered pa
tients were evaluable for response and all patients were evaluable for
toxicity. Eleven of 19 patients achieved stable disease. Median time
to progression after start of treatment was 57 days, for the 18 patien
ts for whom the date of progression is known. There were no partial or
complete responses. Hematologic toxicity was dose limiting with grade
3-4 neutropenia in 50 percent of patients and 4 deaths associated wit
h neutropenic sepsis. Non-hematologic toxicity was mild to moderate wi
th nausea and vomiting predominating. In this study, amonafide was a m
yelotoxic, inactive treatment in advanced/recurrent head and neck canc
er. Further use in head and neck cancer appears unwarranted.